Molecular wipes: application to epidemic keratoconjuctivitis

Karolina Aplander,^{a†} Marko Marttila,^{b†} Sophie Manner,^a Niklas Arnberg,^{b,c} Olov Sterner,^a Ulf Ellervik^{a*}

a) Center for Analysis and Synthesis, Chemical Center, Lund University, P. O. Box 124, SE-221 00 Lund, Sweden. b) Division of Virology, Department of Clinical Microbiology, Umeå University SE-90185, Umeå, Sweden. c) Laboratory for Molecular Infection Medicine in Sweden (MIMS), Umeå University

* Corresponding author. Phone: +46-46-2228220; Fax: +46-46-2228209; e-mail: ulf.ellervik@organic.lu.se.

TABLE OF CONTENTS

S2
S6
S 7
S 8
S9
S10
S11
S12
S 13
S14
S15
S16
S17
S18

6,19-diaza-22-(9H-fluoren-9-yl)-10,13,16,21-tetraoxa-7,20-dioxo-dokosanyl methyl(5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-a-D-galacto-2nonylopyranosyl)onate (2a). 1 (151 mg, 0.189 mmol) was dissolved in dry DMF (5 mL) and then piperidine (706 µL, 7.14 mmol) was added to the solution. The reaction mixture was stirred for 2h after which the solvent and remaining piperidine were evaporated under reduced pressure to give a crude intermediate. This crude intermediate (36.3 mg, 0.063 mmol) and Fmoc-NH-CH₂CH₂O-(PEG)₂-CH₂CH₂-COOH were dissolved in DCM (1 mL) and the solution was cooled to 0 °C. EDC•HCl (18.2 mg, 0.095 mmol) was added to the solution and the reaction mixture was stirred for 18 h. The crude was subjected to flash column chromatography (DCM/MeOH 25:1) to give 2a (45.0 mg, 71%). ¹H NMR (400 MHz, CDCl₃) δ 1.28-1.57 (m), 1.87 (s, 3H), 1.90-1.96 (m), 2.01 (s, 3H), 2.02 (s, 3H), 2.13 (s, 3H), 2.13 (s, 3H), 2.42 (t, 2H), 2.53-2.58 (m, 1H), 3.17-3.27 (m, 3H), 3.38-3.40 (m), 3.55-3.62 (m), 3.68-3.78 (m), 4.02-4.10 (m, 3H) 4.21 (t, 1H), 4.29-4.33 (m, 1H), 4.40 (d, 2H), 4.79-4.86 (m, 1H), 5.19-5.22 (m, 1H), 5.29-5.32 (m, 1H), 5.37-5.44 (m, 2H), 6.37 (t, 1H), 7.28-7.32 (m, 2H), 7.39 (t, 2H), 7.60 (d, 2H), 7.76 (d, 2H). HRMS calcd. for $C_{49}H_{67}N_{3}O_{19}$ (M+Na)⁺ 1024.4266, found 1024.4921.

6,25-diaza-28-(9H-fluoren-9-yl)-10,13,16,19,22,28-hexaoxa-7,26-dioxo-

oktaeikosanyl methyl(5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero- α -D-galacto-2-nonylopyranosyl)onate (2b). The following compound was synthesized in an analogous method to compound 2a, using Fmoc-NH-CH₂CH₂O-(PEG)₄-CH₂CH₂-COOH instead of Fmoc-NH-CH₂CH₂O-(PEG)₂-CH₂CH₂-COOH. Yield 83.4 mg (61%). ¹H NMR (400 MHz, CDCl₃) δ 1.27-1.57 (m), 1.86-2.04 (m), 2.13 (s, 6H), 2.43 (t, 2H), 2.53-2.58 (m, 1H), 3.17-3.24 (m, 3H), 3.36-3.40 (m), 3.55-3.62 (m), 3.68-3.77 (m), 4.02-4.11 (m, 3H), 4.21 (t, 1H), 4.29-4.32 (m, 1H), 4.39 (d, 2H), 4.79-4.85 (m, 1H), 5.23-5.25 (m, 1H), 5.29-5.32 (m, 1H), 5.36-5.40 (m, 1H), 5.48 (t, 1H), 6.47 (t, 1H), 7.28-7.32 (m, 2H), 7.37-7.41 (m, 2H), 7.60 (d, 2H), 7.75 (d, 2H). HRMS calcd. for C₅₃H₇₅N₃O₂₁ (M+Na)⁺ 1112.4791, found 1112.5548.

6,46-diaza-49-(9H-fluoren-9-yl)-10,13,16,19,22,25,28,31,34,37,40,43,48-

tridekaoxa-7,47-dioxo-nonatetrakontanyl methyl(5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-nonylopyranosyl)onate (2c). The following compound was synthesized in an analogous method to compound 2a, using Fmoc-NH-CH₂CH₂O-(PEG)₁₁-CH₂CH₂-COOH instead of Fmoc-NH-CH₂CH₂O-(PEG)₂-CH₂CH₂-COOH. Yield 45.8 mg (60%). ¹H NMR (400 MHz, CDCl₃) δ 1.23-1.57 (m), 1.86 (s, 3H), 1.88-1.98 (m), 2.01 (s, 3H), 2.02 (s, 3H), 2.12 (s, 6H), 2.43 (t, 2H), 2.53-2.57 (m, 1H), 3.16-3.27 (m, 3H), 3.37-3.43 (m, 2H), 3.54-3.62 (m), 3.69-3.75 (m), 3.75-3.77 (m), 4.01-4.10 (m), 4.20 (t, 1H), 4.28-4.32 (m, 1H), 4.34-4.39 (m, 2H), 4.78-4.85 (m, 1H), 5.24-5.31 (m, 2H), 5.35-5.39 (m, 1H), 5.43 (t, 1H), 6.50 (t, 1H), 7.27-7.31 (m, 2H), 7.36-7.40 (m, 2H), 7.58-7.63 (m, 2H), 7.74 (d, 2H). HRMS calcd. for C₆₇H₁₀₃N₃O₂₈ (M+Na)⁺ 1420.6626, found 1420.7222.

6,25-diaza-10,13,16,19,22-pentaoxa-7,26-dioxo-tritetrakontanyl methyl(5acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-

nonylopyranosyl)onate (3). **2b** (26.7 mg, 0.024 mmol) was dissolved in DMF (1.5 mL) and then piperidine (92 μ L, 0.93 mmol) was added. The reaction mixture was stirred for 3 h. The solvent was evaporated to give a crude intermediate. The crude intermediate was dissolved in DCM (1.5 mL) and then stearic acid (10.2 mg, 0.036 mmol) was added to the solution and the reaction was cooled to 0 °C. EDC•HCl (6.9 mg, 0.036 mmol) was added to the solution. The reaction mixture was stirred for 17 h. The reaction mixture was washed with water, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude was subjected to flash column

chromatography (DCM/MeOH 25:1) to give **3** (14.2 mg, 52% over two steps). ¹H NMR (400 MHz, CDCl₃) δ 0.88 (t), 1.25-1-42 (m), 1.46-1.67 (m), 1.79-1.83 (m), 1.88 (s, 3H), 1.91-1.97 (m), 2.03, (s, 3H), 2.04 (s, 3H), 2.10-2.19 (m), 2.44-2.47 (t, 2H), 2.54-2.60 (m), 3.18-3.33 (m), 3.42-3.46 (m, 2H), 3.54-3.56 (m, 2H), 3.61-3.65 (m), 3.71-3.77 (m), 3.79 (s, 3H), 4.02-4.11 (m, 3H), 4.30-4.33 (m, 1H), 4.80-4.87 (m, 1H), 5.15.5.17 (m, 1H), 5.30-5.33 (m, 1H), 5.37-5.41 (m, 1H), 6.18 (t, 1H), 6.51 (t, 1H). HRMS calcd. for C₅₆H₉₉N₃O₂₀ (M+Na)⁺ 1156.6720, found 1156.7217.

6,25-diaza-10,13,16,19,22-pentaoxa-7,26-dioxo-nonatetrakontanyl methyl(5acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-

nonylopyranosyl)onate (4). Compound **4** was synthesized in an analogous method to compound **3**, using **2b** and tetracosanoic acid. Yield 18.3 mg (63%). ¹H NMR (400 MHz, CDCl₃) δ 0.87 (t, 3H), 1.24-1.40 (m), 1.46-1.62 (m), 1.87 (s, 3H), 1.90-1.96 (m), 2.02 (s, 3H), 2.03 (s, 3H), 2.10-2.18 (m), 2.43-2.46 (t, 2H), 2.54-2.59 (m), 3.17-3.30 (m), 3.41-3.45 (m, 2H), 3.53-3.56 (m, 2H), 3.60-3.64 (m), 3.70-3.76 (m), 3.78 (s, 3H), 4.02-4.11 (m), 4.29-4.33 (m, 1H), 4.79-4.86 (m, 1H), 5.22-5.24 (m, 1H), 5.29-5.32 (m, 1H), 5.36-5.40 (m, 1H), 6.15 (t, 1H), 6.51 (t, 1H). HRMS calcd. for C₆₂H₁₁₁N₃O₂₀ (M+H)⁺ 1218.7839, found 1218.7875.


6,19-diaza-10,13,16-trioxa-7,20-dioxo-29,31-tetratetrakonta-diynyl methyl(5acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-


nonylopyranosyl)onate (**5a**). Compound **5a** was synthesized in an analogous method to compound **3**, using **2a** and 10,12-pentacosadiynoic acid. Yield 36.3 mg (73%). ¹H NMR (400 MHz, CDCl₃) δ 0.86 (t, 3H), 1.23-1.41 (m), 1.42-1.61 (m), 1.86 (s, 3H), 1.89-1.97 (m), 2.01 (s, 3H), 2.02 (s, 3H), 2.08-2.18 (m), 2.20-2.23 (m), 2.43 (t, 2H), 2.53-2.59 (m, 1H), 3.18-3.31 (m), 3.4-3.44 (m, 2H), 3.52-3.55 (m, 2H), 3.59-3.62 (m), 3.69-3.75 (m), 3.77 (s, 3H), 4.01-4.10 (m), 4.28-4.32 (m, 1H), 4.78-4.85 (m, 1H),

5.28-5.39 (m, 3H), 6.11 (t, 1H), 6.43 (t, 1H). HRMS calcd. for $C_{59}H_{97}N_3O_{18}$ (M+Na)⁺ 1158.6665, found 1158.6655.


6,25-diaza-10,13,16,19,22-pentaoxa-7,26-dioxo-35,37-pentakontadiynyl methyl(5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2nonylopyranosyl)onate (5b). Compound 5b was synthesized in an analogous method to compound 3, using 2b and 10,12-pentacosadiynoic acid. Yield 21.9 mg (62%). ¹H NMR (400 MHz, CDCl₃) δ 0.86 (t, 3H), 1.24-1.39 (m), 1.45-1.62 (m), 1.86 (s, 3H), 1.92-1.95 (m), 2.01 (s, 3H), 2.02 (s, 3H), 2.10-2.17 (m), 2.20-2.24 (m), 2.45 (t, 2H), 2.53-2.59 (m), 3.17-3.31 (m), 3.41-3.45 (m, 2H), 3.53-3.55 (m, 2H), 3.61-3.64 (m), 3.70-3.76 (m), 3.78 (s, 3H), 4.01-4.10 (m), 4.28-4.35 (m, 1H), 4.78-4.85 (m, 1H), 5.26-5.31 (m, 2H), 5.35-5.40 (m, 1H), 6.19 (t, 1H), 6.52 (t, 1H). HRMS calcd. for $C_{63}H_{105}N_3O_{20}$ (M+Na)⁺ 1246.7189, found 1246.7118.


6,46-diaza-10,13,16,19,22,25,28,31,34,37,40,43,46-dodekaoxa-7,47-dioxo-56,58henheptakonta-diynyl methyl(5-acetamido-4,7,8,9-tetra-*O*-acetyl-3,5-dideoxy-Dglycero-α-D-galacto-2-nonylopyranosyl)onate (5c). Compound 5c was synthesized in an analogous method to compound 3, using 2c and 10,12-pentacosadiynoic acid. Yield 25.2 mg (50%). ¹H NMR (400 MHz, CDCl₃) δ 0.87 (t, 3H), 1.24-1.41 (m), 1.46-1.62 (m), 1.87 (s, 3H), 1.90-2.02 (m), 2.03 (s, 3H), 2.05 (s, 3H), 2.13-2.18 (m), 2.21-2.24 (m), 2.46 (t, 2H), 2.54-2.58 (m, 1H), 3.17-3.26 (m), 3.42-3.49 (m), 3.54-3.56 (m), 3.62-3.65 (m), 3.70-3.75 (m), 3.79 (s, 3H), 4.02-4.11 (m), 4.29-4.32 (m, 1H), 4.79-4.86 (m, 1H), 5.17-5.20 (m, 1H), 5.29-5.32 (m, 1H), 5.36-5.40 (m, 1H), 6.17 (s, 1H), 6.58 (s, 1H). HRMS calcd. for C₇₇H₁₃₃N₃O₂₇ (M+Na)⁺ 1554.9024, found 1554.9325.








S7

















S14

